Remdesivir
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Remdesivir: From an Antiviral Injection to Multiple Endocrine Neoplasia
One-Sentence Summary
Remdesivir is a nucleotide analogue antiviral that inhibits viral RNA polymerase. It is marketed in Singapore as an intravenous infusion, and the approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be effective for multiple endocrine neoplasia (score 99.5%), but there are 0 clinical trials and 0 publications supporting this prediction. This is a model prediction only, with no identifiable mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the Singapore licence does not list indication text) |
| Predicted New Indication | Multiple endocrine neoplasia |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. From general knowledge, remdesivir is a nucleotide analogue prodrug that inhibits viral RNA-dependent RNA polymerase, which is the basis of its antiviral activity.
Multiple endocrine neoplasia is a hereditary tumour syndrome (for example, MEN1 or RET mutations). Its biology has no connection to viral RNA polymerase inhibition. The high TxGNN score is therefore best read as a statistical artefact of the knowledge-graph model, not a mechanistically grounded signal.
For context, the other top predictions are also weakly supported:
- HIV infection (score 99.3%, evidence L4): the only prediction with a clinical trial, but that trial (NCT04385719) is a pharmacokinetic drug-interaction study in healthy volunteers, not an efficacy study. The literature is almost entirely about COVID-19.
- Cytomegalovirus infection (score 97.1%, evidence L4): the literature covers CMV co-infection in COVID-19 patients and does not show remdesivir efficacy against CMV.
- Leprosy, simian and feline immunodeficiency, and several genetic or cardiovascular conditions: no plausible mechanistic link, with prediction-only or reverse-direction evidence.
Clinical Trial Evidence
Currently no related clinical trials are registered for multiple endocrine neoplasia.
Literature Evidence
Currently no related literature available for multiple endocrine neoplasia.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15950P | VEKLURY® Lyophilized Powder for IV Infusion 100 mg/vial | Injection, powder, lyophilized, for solution | Not listed |
Cytotoxicity
Remdesivir is an antiviral, not an antineoplastic agent, so this assessment does not apply.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 interacting drugs. The 20 shown to the report are all rated Moderate. Examples include:
- Antibiotics: doxycycline, minocycline, tetracycline, clarithromycin, levofloxacin, vancomycin, kanamycin, neomycin
- Antifungals: amphotericin B, including the lipid complex formulation
- Diabetes drugs: acarbose, pioglitazone
- Others: bupropion, naltrexone, mesalazine, balsalazide, olsalazine, chenodeoxycholic acid, oxandrolone, oxymetholone
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (evidence level L5). There are no trials or publications, and remdesivir's antiviral mechanism has no plausible link to a hereditary endocrine tumour syndrome. Prediction scores this high do not substitute for biological rationale.
To proceed, the following is needed:
- A plausible mechanistic hypothesis connecting remdesivir to multiple endocrine neoplasia, plus preclinical data
- The mechanism-of-action data for remdesivir from DrugBank
- The HSA package insert (warnings, contraindications, approved indication), which is needed before any safety screening
- If antiviral repurposing is of interest, reviewing better-supported directions first (for example, the HIV-related pharmacokinetic work), noting that these also lack efficacy evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.